|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 860 WINTER STREET |
Address2 |
|
City | WALTHAM |
State | MA |
Zip Code | 02451 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 23975-12
|
||||||||
|
6. House ID# 319670000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Lois Dehls Cornell, Executive Vice President |
Date | 10/18/2016 1:01:34 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Comprehensive Addiction and Recovery Act ( CARA) PL 114-198,formerly S. 524/HR 953 - funds to prevent and treat opioid addiction and substance abuse,
Including:
S. 1455 - Treat Act -The Recovery Enhancement for Addiction Act - legislation to increase the # of patients a provider can treat with buprenorphine
S.25781/H.R. 4599 Reducing Unused Medications Act - allows partial fill for Schedule II drugs.
H.R.5057 - Safe Prescribing for Veterans Act - This bill directs the Department of Veterans Affairs (VA) to require a VA employee who is authorized to prescribe any controlled substance to complete at least one accredited continuing education course on pain management every two years
SAMHSA Supplemental Notice of Proposed Rulemaking: Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements [RIN 0930-AA22]
Assistant Secretary for Planning and Evaluation: : Request for Information: Opioid Analgesic Prescriber Education and Training Opportunities to Prevent Opioid Overdose and Opioid Use Disorder
HR 4276/S 2647 - Behavioral Health Coverage Transparency Act - legislation to provide transparency in insurance coverage complying with behavioral health parity requirements
HR 293/S 2978 - the Protecting Continuing Physician Education Act and Patient Care Act - corrections to regulations to implement the Sunshine Act
HR 6 - 21st Century Cures Act - provisions impacting Sunshine Act Regulations
Gun Violence Prevention - support lifting federal ban on research into gun violence and prevention - appropriations
CMS Medicare Part B Drug Demonstration Project - no specific bill
E prescribing for Schedule II drugs - no specific bill
DEA Reclassification of Marijuana to allow scientific research and study - no specific bill
Prescription Drug Pricing - no specific bill
Direct to Consumer Advertising - no specific bill
Negotiating of Part D Drugs - no specific bill
Access to medically tailored foods for low income patients - no specific bill
Meaningful Use and Electronic Medical Records - no specific bill
Medicare Program: Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2017; Medicare Advantage Pricing Data Release; Medicare Advantage and Part D Medical Low Ratio Data Release; Medicare Advantage Provider Network Requirements; Expansion of Medicare Diabetes Prevention Program Model; Proposed Rule (CMS-1654-P); and
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Procurement Organization Reporting and Communication; Transplant Outcome Measures and Documentation Requirements; Proposed Rule (CMS-2016-0115-0002).
Veterans Health Administration Proposed Rule RIN 2900-AP44-Advanced Practice Registered Nurses
National Defense Authorization Act for FY 2017 -issues relating to telemedicine
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Comprehensive Addiction and Recovery Act ( CARA) PL 114-198,formerly S. 524/HR 953 - funds to prevent and treat opioid addiction and substance abuse,
Including:
S. 1455 - Treat Act -The Recovery Enhancement for Addiction Act - legislation to increase the # of patients a provider can treat with buprenorphine
S.25781/H.R. 4599 Reducing Unused Medications Act - allows partial fill for Schedule II drugs.
H.R.5057 - Safe Prescribing for Veterans Act - This bill directs the Department of Veterans Affairs (VA) to require a VA employee who is authorized to prescribe any controlled substance to complete at least one accredited continuing education course on pain management every two years
SAMHSA Supplemental Notice of Proposed Rulemaking: Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements [RIN 0930-AA22]
Assistant Secretary for Planning and Evaluation: : Request for Information: Opioid Analgesic Prescriber Education and Training Opportunities to Prevent Opioid Overdose and Opioid Use Disorder
HR 4276/S 2647 - Behavioral Health Coverage Transparency Act - legislation to provide transparency in insurance coverage complying with behavioral health parity requirements
HR 293/S 2978 - the Protecting Continuing Physician Education Act and Patient Care Act - corrections to regulations to implement the Sunshine Act
HR 6 - 21st Century Cures Act - provisions impacting Sunshine Act Regulations
CMS Medicare Part B Drug Demonstration Project - no specific bill
E prescribing for Schedule II drugs - no specific bill
Prescription Drug Pricing - no specific bill
Negotiating of Part D Drugs - no specific bill
Meaningful Use and Electronic Medical Records - no specific bill
Medicare Program: Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2017; Medicare Advantage Pricing Data Release; Medicare Advantage and Part D Medical Low Ratio Data Release; Medicare Advantage Provider Network Requirements; Expansion of Medicare Diabetes Prevention Program Model; Proposed Rule (CMS-1654-P); and
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Procurement Organization Reporting and Communication; Transplant Outcome Measures and Documentation Requirements; Proposed Rule (CMS-2016-0115-0002).
Veterans Health Administration Proposed Rule RIN 2900-AP44-Advanced Practice Registered Nurses
National Defense Authorization Act for FY 2017 -issues relating to telemedicine
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Comprehensive Addiction and Recovery Act ( CARA) PL 114-198,formerly S. 524/HR 953 - funds to prevent and treat opioid addiction and substance abuse,
Including:
S. 1455 - Treat Act -The Recovery Enhancement for Addiction Act - legislation to increase the # of patients a provider can treat with buprenorphine
S.25781/H.R. 4599 Reducing Unused Medications Act - allows partial fill for Schedule II drugs.
H.R.5057 - Safe Prescribing for Veterans Act - This bill directs the Department of Veterans Affairs (VA) to require a VA employee who is authorized to prescribe any controlled substance to complete at least one accredited continuing education course on pain management every two years
E prescribing for Schedule II drugs - no specific bill
DEA Reclassification of Marijuana to allow scientific research and study - no specific bill
SAMHSA Supplemental Notice of Proposed Rulemaking: Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements [RIN 0930-AA22]
Assistant Secretary for Planning and Evaluation: : Request for Information: Opioid Analgesic Prescriber Education and Training Opportunities to Prevent Opioid Overdose and Opioid Use Disorder
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Prescription Drug Pricing - no specific bill
Direct to Consumer Advertising - no specific bill
Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
Gun Violence Prevention - support lifting federal ban on research into gun violence and prevention - appropriations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
HR 4276/S 2647 - Behavioral Health Coverage Transparency Act - legislation to provide transparency in insurance coverage complying with behavioral health parity requirements
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |